Clinical Trial Update: Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial of lenalidomide for high-risk chronic lymphocytic leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia | Phase 2 | Status: WITHDRAWN